Skip to main content
Clinical Trials/NCT06698406
NCT06698406
Recruiting
N/A

Transcultural Validation of the French Version of the " Patients' Endorsement of a Biopsychosocial Model of Chronic Pain " Scale

Benno Rehberg-Klug1 site in 1 country80 target enrollmentNovember 1, 2024
ConditionsPain, Chronic

Overview

Phase
N/A
Intervention
Not specified
Conditions
Pain, Chronic
Sponsor
Benno Rehberg-Klug
Enrollment
80
Locations
1
Primary Endpoint
incremental validity of the new ABDC scale
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

We will validate the French version of the "Patients' Endorsement of a Biopsychosocial model of chronic pain (PEB) scale" by comparing it to the "pain self-efficacy" questionnaire

Detailed Description

The primary objective is to validate the French version of the PEB scale, called "Echelle d'Adhésion du modèle Bio-psycho-social par des patients avec Douleur Chronique ABDC". The hypothesis is that the ABDC scale is a valid measurement tool to measure and operationalize beliefs about the biopsychosocial nature of pain in adults with chronic pain. Consenting patients will receive paper copies of the study questionnaire including the questionnaires named in the secondary outcomes section, except those which are already included in the standard evaluation questionnaire of the pain consultation (BPI, GAD-7, PHQ-9). Patients will return the questionnaire either at a the same or a follow-up consultation, or send in the questionnaire by post in a prepaid envelope.

Registry
clinicaltrials.gov
Start Date
November 1, 2024
End Date
November 1, 2025
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Benno Rehberg-Klug
Responsible Party
Sponsor Investigator
Principal Investigator

Benno Rehberg-Klug

Clinical professor

University Hospital, Geneva

Eligibility Criteria

Inclusion Criteria

  • - Patients with chronic pain (defined by ICD-11 as pain persisting or recurring longer than 3 months) having a chronic pain consultation at the HUG
  • French-speaking and able to understand the study information
  • ≥18 years of age

Exclusion Criteria

  • - Inability to understand the consent form and the questionnaire, e.g. due to lan-guage problems, psychological disorders, dementia, etc. of the participant
  • Enrolment of the investigator, his/her family members, employees and other de-pendent persons

Outcomes

Primary Outcomes

incremental validity of the new ABDC scale

Time Frame: 1 day

Incremental validity is the degree to which a new scale increases the ability to predict an outcome beyond existing parameters and scales. In our case pain self-efficacy, measured by the "pain self-efficacy questionnaire" \[8\], which exists in a validated French version \[9\], is the outcome to be predicted. Hierarchical regression analysis will have four models including in hierarchical order 8 explanatory variables: demographical variables (gender, age, level of education), depressive symptoms and anxiety, pain catastrophizing, pain acceptance, and finally the ABDC scale

Secondary Outcomes

  • Reliability of the ABDC scale(1 day)
  • Convergent validity(1 day)
  • Discriminant validity(1 day)

Study Sites (1)

Loading locations...

Similar Trials